During the third quarter, two notable shifts occurred in major institutional stakes of Eli Lilly and Company. Alta Wealth Advisors LLC reduced its position by 17.0%, selling 522 shares and finishing the period with 2,541 shares valued at $1.94 million. In contrast, First Citizens Bank & Trust Co. boosted its holding by 58.8%, acquiring an additional 9,121 shares to reach 24,634 shares worth $18.80 million. Overall, institutions and hedge funds now control approximately 82.53% of outstanding shares, reflecting continued confidence in Eli Lilly’s long-term growth trajectory despite tactical portfolio adjustments.

In the quarter ended October 30, the company reported earnings per share of $7.02, outpacing the consensus estimate of $6.42 by $0.60. Revenue rose 53.9% year-over-year to $17.60 billion, surpassing analysts’ forecast of $16.09 billion. Net margin improved to 30.99%, while return on equity reached 109.52%. Management set full-year 2025 EPS guidance in a range of $23.00 to $23.70. Street analysts project an average of $23.48, suggesting alignment between company outlook and market expectations for continued high-margin growth driven by key therapies in immunology and metabolic diseases.

Eli Lilly declared a quarterly dividend of $1.73 per share, payable on March 10 to shareholders of record on February 13. This represents a 15.3% increase over the prior quarterly payout of $1.50, translating to an annualized dividend of $6.92 and a yield of approximately 0.7%. The dividend payout ratio stands at 29.35%, balancing attractive shareholder returns with reinvestment in research and development. The move underscores the company’s commitment to returning excess cash flow while funding a robust clinical pipeline.

The company’s market capitalization remains near $1.01 trillion, underpinned by a price-to-earnings ratio of about 52.0 and a price/earnings-growth ratio of 0.80. Trading within a 52-week range of roughly $623.78 to $1,133.95, the stock exhibits moderate volatility with a beta of 0.35. On the balance sheet, liquidity ratios are healthy, with a current ratio of 1.55 and a quick ratio of 1.24, while debt-to-equity sits at 1.71. These metrics highlight ample capacity to invest in new drug development and potential acquisitions without compromising financial flexibility.